|
Dr Tan Min-Han
Founding Chief Executive Officer and Medical Director
Lucence Health, Singapore
|
|
Dr. Tan Min-Han is the founding CEO and Medical Director of Lucence Health, a medical company that delivers liquid biopsy testing for earlier cancer detection in patients. Lucence operates twin CAP and CLIA laboratories in Singapore and Palo Alto, and is the first and only Asian-headquartered healthcare company to receive United States Medicare national insurance coverage for its technology services. Lucence has supported LIQUIK, a landmark study as the world's only head-to-head prospective multicenter study evaluating liquid biopsy in cancer care.
Dr Tan is a medical oncologist and clinical cancer geneticist who graduated from the National University of Singapore (NUS) in 1998, trained at the National Cancer Center Singapore and the Cleveland Clinic, and completed a PhD in molecular epidemiology and biostatistics at the Karolinska Institute and NUS. He led a research laboratory at A*STAR from 2011, focusing on liquid biopsies, eventually founding Lucence as a spin-off company in 2017.
Session: Bespoke Healthcare (Efforts to Tailor the Healthcare Journey for Patients) Presenting Title: Multi-Cancer Early Detection (MCED) Blood Testing for Cancer Screening in Asia
Asia is facing a cancer tsunami in the next
30 years, with an aging population and lifestyle changes. Over 8 million new
cancer cases occur in Asia annually, with the majority presenting in late
stage. 78% of cancer-related deaths occur in cancers that lack effective
screening methods. Compliance with traditional screening methods like
mammograms are low, and availability of screening resources are limited, with
limited resources to handle false positives. There is a need for accurate,
accessible, and affordable approaches for earlier cancer detection, when it is
most treatable. Multi-cancer early detection (MCED) blood tests are now
commercially available for use in addition to traditional screening methods to
address the gaps described above. This talk will discuss the development of
Asia-based MCED testing to address the upcoming cancer challenges in Asia. |
Get trusted health advice, offers and more.
Subscribe to our exclusive updates for healthcare professionals.
Stay Healthy With
HealthXchange
Health Videos